https://therivabio.com/resource/vcn-01-disrupts-pancreatic-cancer-stroma-and-exerts-antitumor-effects/ 2023-03-08T05:39:42+00:00 https://therivabio.com/resource/vcn-01-is-an-encouraging-therapy-against-retinoblastoma/ 2023-03-08T06:48:22+00:00 https://therivabio.com/resource/therapeutic-targeting-of-the-rb1-pathway-in-retinoblastoma-with-the-oncolyticadenovirus-vcn-01/ 2023-03-08T06:52:09+00:00 https://therivabio.com/resource/phase-i-multicenter-open-label-study-of-intravenous-vcn-01-oncolytic-adenovirus-with-or-without-nab-paclitaxel-plus-gemcitabine-in-patients-with-advanced-solid-tumors/ 2023-03-08T06:54:24+00:00 https://therivabio.com/resource/oncolytic-adenovirus-with-hyaluronidase-activity-that-evades-neutralizing-antibodies-vcn-11/ 2023-03-08T07:06:36+00:00 https://therivabio.com/resource/characterization-of-clostridium-difficile-isolates-collected-during-a-phase-2b-clinical-study-with-syn-004-ribaxamase-for-the-prevention-of-c-difficile-infection/ 2023-03-08T07:09:52+00:00 https://therivabio.com/resource/tolerability-and-pharmacokinetics-of-syn-004-an-orally-administered-β-lactamase-for-the-prevention-of-clostridium-difficile-associated-disease-and-antibiotic-associated-diarrhea-in-two-phase-1/ 2023-03-08T07:13:05+00:00 https://therivabio.com/resource/the-oral-β-lactamase-syn-004-ribaxamase-degrades-ceftriaxone-excreted-into-the-intestine-in-phase-2a-clinical-studies/ 2023-03-08T07:15:18+00:00 https://therivabio.com/resource/use-of-ribaxamase-syn-004-a-β-lactamase-to-prevent-clostridium-difficile-infection-in-β-lactam-treated-patients-a-double-blind-phase-2b-randomised-placebo-controlled-trial/ 2023-03-08T07:18:10+00:00 https://therivabio.com/resource/vcn-01-penetra-en-las-celulas-tumorales-y-las-elimina/ 2024-03-07T15:37:36+00:00 https://therivabio.com/resource/how-theriva-biologics-is-using-an-adenovirus-to-develop-a-novel-treatment-for-pancreatic-cancer-as-well-as-other-cancers-with-an-unmet-need/ 2024-03-19T10:46:28+00:00